{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hCG+%28human+chorionic+gonadotropin%29&page=3",
    "query": {
      "intervention": "hCG (human chorionic gonadotropin)",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 50,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hCG+%28human+chorionic+gonadotropin%29&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hCG+%28human+chorionic+gonadotropin%29&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T03:35:20.855Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00042952",
      "title": "Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Dysgerminoma",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Ovarian Germ Cell Tumor",
        "Stage II Malignant Testicular Germ Cell Tumor",
        "Stage II Ovarian Germ Cell Tumor",
        "Stage III Malignant Testicular Germ Cell Tumor",
        "Stage III Ovarian Germ Cell Tumor",
        "Testicular Seminoma"
      ],
      "interventions": [
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2002-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-17",
      "last_synced_at": "2026-10-08T03:35:20.855Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042952"
    },
    {
      "nct_id": "NCT02069808",
      "title": "Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Egg Donation"
      ],
      "interventions": [
        {
          "name": "Follistim",
          "type": "DRUG"
        },
        {
          "name": "Ganirelix",
          "type": "DRUG"
        },
        {
          "name": "Menotropins",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide",
          "type": "DRUG"
        },
        {
          "name": "Transvaginal ultrasound guided needle aspiration of oocytes",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Michigan Reproductive Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "28 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 28 Years · Female only"
      },
      "enrollment_count": 38,
      "start_date": "2014-04",
      "completion_date": "2017-03-08",
      "has_results": false,
      "last_update_posted_date": "2018-03-23",
      "last_synced_at": "2026-10-08T03:35:20.855Z",
      "location_count": 1,
      "location_summary": "Bloomfield Hills, Michigan",
      "locations": [
        {
          "city": "Bloomfield Hills",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02069808"
    },
    {
      "nct_id": "NCT01094496",
      "title": "A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The \"N-ABLE\" Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "CDX-1307 Vaccine Regimen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2010-04",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2020-02-13",
      "last_synced_at": "2026-10-08T03:35:20.855Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01094496"
    },
    {
      "nct_id": "NCT01815138",
      "title": "Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ovarian Hyperstimulation Syndrome"
      ],
      "interventions": [
        {
          "name": "hCG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UConn Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 39 Years · Female only"
      },
      "enrollment_count": 89,
      "start_date": "2013-03",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2018-10-26",
      "last_synced_at": "2026-10-08T03:35:20.855Z",
      "location_count": 1,
      "location_summary": "Farmington, Connecticut",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01815138"
    },
    {
      "nct_id": "NCT04886726",
      "title": "PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "uhCG/EGF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 18,
      "start_date": "2021-12-23",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-10-08T03:35:20.855Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04886726"
    },
    {
      "nct_id": "NCT01786252",
      "title": "Effect of hCG on Receptivity of the Human Endometrium",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infertility",
        "Subfertility"
      ],
      "interventions": [
        {
          "name": "human chorionic gonadotropin (hCG)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator (for hCG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michigan State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "34 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 34 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2013-01",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2017-02-24",
      "last_synced_at": "2026-10-08T03:35:20.855Z",
      "location_count": 1,
      "location_summary": "Grand Rapids, Michigan",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01786252"
    },
    {
      "nct_id": "NCT00839319",
      "title": "HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy Males"
      ],
      "interventions": [
        {
          "name": "Acyline",
          "type": "DRUG"
        },
        {
          "name": "placebo hCG (no active ingredient)",
          "type": "OTHER"
        },
        {
          "name": "hCG (human chorionic gonadotropin)",
          "type": "DRUG"
        },
        {
          "name": "Testosterone gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 59,
      "start_date": "2009-03",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2016-01-11",
      "last_synced_at": "2026-10-08T03:35:20.855Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00839319"
    },
    {
      "nct_id": "NCT00715364",
      "title": "REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "NTx™-265: rhCG, then rEPO",
          "type": "DRUG"
        },
        {
          "name": "Saline Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stem Cell Therapeutics Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2009-08",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2011-09-05",
      "last_synced_at": "2026-10-08T03:35:20.855Z",
      "location_count": 2,
      "location_summary": "Newport Beach, California • Orange, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00715364"
    },
    {
      "nct_id": "NCT00700778",
      "title": "Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "BRCA1 Mutation",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant human chorionic gonadotropin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "microarray analysis",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "needle biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "20 Years to 40 Years · Female only"
      },
      "enrollment_count": 2,
      "start_date": "2008-07",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2021-01-25",
      "last_synced_at": "2026-10-08T03:35:20.855Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00700778"
    },
    {
      "nct_id": "NCT00505752",
      "title": "Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infertility"
      ],
      "interventions": [
        {
          "name": "AS900672-Enriched 50 microgram (mcg)",
          "type": "DRUG"
        },
        {
          "name": "AS900672-Enriched 100 mcg",
          "type": "DRUG"
        },
        {
          "name": "AS900672-Enriched 150 mcg",
          "type": "DRUG"
        },
        {
          "name": "Follitropin alfa 150 international unit (IU)",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human chorionic gonadotropin (r-hCG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "36 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 36 Years · Female only"
      },
      "enrollment_count": 520,
      "start_date": "2007-01",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-02-13",
      "last_synced_at": "2026-10-08T03:35:20.855Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00505752"
    }
  ]
}